The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Open accessAbstract
Background: We previously showed that therapy with anti–checkpoints T-lymphocyte-associated protein 4 (anti–CTLA-4) or antiprogrammed cell death protein 1 (anti–PD-1) agents was more effective for men as compared with women. However, because the sex-dimorphism of the immune system is complex, involving multiple elements of immune responses, it is possible that women could derive larger benefit than men from strategies other than therapy with immune checkpoint inhibitors (ICIs) alone. Here we investigated whether women could derive larger benefit than men from the combination of chemotherapy and anti-PD-1 or anti-PD-L1. Methods: We performed two meta-analyses. The first included all randomized controlled trials (RCTs) testing anti-PD1 and anti–PD-L1 plus chemotherapy vs chemotherapy to assess different efficacy between men and women. The second included all RCTs of first-line systemic treatment in advanced non-small cell lung cancer testing anti–PD-1/PD-L1 given either alone or combined with chemotherapy to assess the different efficacy of these two immunotherapeutic strategies according to patients’ sex. For each RCT included in the two meta-analyses, first, a trial-specific ratio of hazard ratios (HRs) was calculated from the ratio of the reported hazard ratios in men and in women; second, these trial-specific ratios of hazard ratios were combined across trials using a random-effects model to obtain a pooled hazard ratios ratio. A pooled HRs ratio estimate lower than 1 indicates a greater treatment effect in men, and higher than 1 a greater effect in women. Results: Eight RCTs were included in the first meta-analysis. The pooled overall survival hazard ratios (OS-HRs) comparing anti–PD-1/PD-L1 plus chemotherapy vs chemotherapy was 0.76 (95% confidence interval [CI] = 0.66 to 0.87) for men and 0.48 (95% CI = 0.35 to 0.67) for women. The pooled ratio of the overall survival hazard ratios reported in men vs women was 1.56 (95% CI = 1.21 to 2.01), indicating a statistically significant greater effect for women. Six RCTs were included in the second meta-analysis: three tested an anti-PD-1 alone, whereas three RCTs tested anti-PD-1/PD-L1 plus chemotherapy. The pooled overall survival hazard ratios were 0.78 (95% CI = 0.60 to 1.00) in men and 0.97 (95% CI = 0.79 to 1.19) in women for anti–PD-1 alone, compared with 0.76 (95% CI = 0.64 to 0.91) in men and 0.44 (95% CI = 0.25 to 0.76) in women for anti–PD-1/PD-L1 plus chemotherapy. The pooled ratio of overall survival hazard ratios was 0.83 (95% CI = 0.65 to 1.06) for anti–PD-1 alone, indicating a greater effect in men, and 1.70 (95% CI = 1.16 to 2.49) for anti–PD-1/PD-L1 plus chemotherapy, indicating a greater effect in women. Conclusion: Women with advanced lung cancer derived a statistically significantly larger benefit from the addition of chemotherapy to anti–PD-1/PD-L1 as compared with men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two meta-analyses of 20 and 14 randomized clinical trials, involving more than 15,000 patients diagnosed with different indications, found that although ICIs enhance anti-cancer responses in both men and women, men appear to experience a modestly greater benefit.51,52”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Cited by
Sorted by citations
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00348-y · Cited by 350
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J. K., Krebs, T., Lim, F., Chang, C., & McDonnell, D. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 283
Sex-associated molecular differences for cancer immunotherapy
Ye, Y., Jing, Y., Liang, L., Mills, G. B., Diao, L., Liu, H., & Han, L. (2020) · Nature Communications · doi:10.1038/s41467-020-15679-x · Cited by 255
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
Genome-Wide Sex and Gender Differences in Cancer
Lopes‐Ramos, C. M., Quackenbush, J. F., & DeMeo, D. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.597788 · Cited by 168
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 159
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M., & Loges, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01184 · Cited by 149
“In this study, the results concluded that women had better responses to the combination of ICI and chemotherapy compared with men, while men responded better to either chemotherapy or ICI therapy alone compared with women (157).”
ResultGender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
Mederos, N., Friedlaender, A., Peters, S., & Addeo, A. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000796 · Cited by 135
The spectrum of sex differences in cancer
Rubin, J. B. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.013 · Cited by 132
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 129
Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma
Lee, J., Nicosia, M., Hong, E. S., Silver, D. J., Li, C., Bayık, D., Watson, D. C., Lauko, A. J., Kay, K. E., Wang, S. Z., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0869 · Cited by 133
Sex and Gender Influences on Cancer Immunotherapy Response
Irelli, A., Sirufo, M. M., D’Ugo, C., Ginaldi, L., & Martinis, M. D. (2020) · Biomedicines · doi:10.3390/biomedicines8070232 · Cited by 109
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., Pas, T. M. D., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0136 · Cited by 107
Self-citationMacDonald, W., Purcell, C., Pinho-Schwermann, M. P., Stubbs, N. M., Srinivasan, P. R., & El‐Deiry, W. S. (2025) · Cancers · doi:10.3390/cancers17030441 · Cited by 119
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 104
Conforti, F., Pala, L., Pagan, E., Corti, C., Bagnardi, V., Queirolo, P., Catania, C., Pas, T. M. D., & Giaccone, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100251 · Cited by 93
Self-citationProgrammed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Solinas, C., Aiello, M. M., Rozali, E. N., Lambertini, M., Willard-Gallo, K. E., & Migliori, E. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100811 · Cited by 93
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105
The evolving landscape of sex-based differences in lung cancer: a distinct disease in women
Ragavan, M. V., & Patel, M. I. (2022) · European Respiratory Review · doi:10.1183/16000617.0100-2021 · Cited by 88
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 89
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, P., Novelli, L., Galdiero, M. R., Chimenti, M. S., Conigliaro, P., Perricone, R., Perricone, C., & Gerli, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102590 · Cited by 85
Therapeutic vaccines for breast cancer: Has the time finally come?
Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.027 · Cited by 84
Smida, T., Bruno, T. C., & Stabile, L. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00137 · Cited by 84
Peng, L., Qin, B., Xiao, K., Xu, S., Yang, J., Zang, Y., Stebbing, J., & Xie, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781333 · Cited by 84
Sex difference in human diseases: mechanistic insights and clinical implications
Shi, Y., Ma, J., Li, S., Liu, C., Liu, Y., Chen, J., Liu, N., Liu, S., & Huang, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01929-7 · Cited by 91
Sex and cancer immunotherapy: Current understanding and challenges
Pala, L., Pas, T. M. D., Catania, C., Giaccone, G., Mantovani, A., Minucci, S., Viale, G., Gelber, R. D., & Conforti, F. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.005 · Cited by 73
Self-citationLung Cancer in Women: The Past, Present, and Future
Florez, N., Kiel, L., Riaño, I., Patel, S. R., DeCarli, K., Dhawan, N., Franco, I., Odai-Afotey, A. A., Meza, K., Swami, N. S., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.10.007 · Cited by 77
Guislain, P. (1997) · Cited by 71
Passaro, A., Attili, I., Morganti, S., Signore, E. D., Gianoncelli, L., Spitaleri, G., Stati, V., Catania, C., Curigliano, G., & de Marinis, F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102085 · Cited by 65
Role of sex hormones in lung cancer
Fuentes, N., Rodriguez, M. S., & Silveyra, P. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211019697 · Cited by 67
Outcome differences by sex in oncology clinical trials
Kammula, A. V., Schäffer, A. A., Rajagopal, P. S., Kurzrock, R., & Ruppin, E. (2024) · Nature Communications · doi:10.1038/s41467-024-46945-x · Cited by 66
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 65
Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence
Slawinski, C., Barriuso, J., Guo, H., & Renehan, A. G. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.05.004 · Cited by 65
Dudnik, E., Moskovitz, M. T., Rottenberg, Y., Lobachov, A., Mandelboim, R., Shochat, T., Urban, D., Wollner, M., Nechushtan, H., Rotem, O., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1865653 · Cited by 62
Qin, B., Jiao, X., Liu, J., Liu, K., He, X., Wu, Y. X., Ling, Y., Duan, X.-P., Qin, W., Wang, Z., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102893 · Cited by 60
Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells
Wang, Z., Li, W., Wang, X., Zhu, Q., Liu, L., Qiu, S., Zou, L., Liu, K., Li, G., Miao, H., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002675 · Cited by 60
Tricarico, R., Nicolas, É., Hall, M. J., & Golemis, E. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1741 · Cited by 62
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Gee, K. N., & Yendamuri, S. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-744 · Cited by 63
Moutafi, M. K., Tao, W., Huang, R. S. P., Haberberger, J., Alexander, B. M., Ramkissoon, S. H., Ross, J. S., Syrigos, K., Wei, W., Pusztai, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002230 · Cited by 53
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 61
Qin, B., Jiao, X., Zhou, X.-C., Shi, B., Wang, J., Liu, K., Wu, Y., Ling, Y., & Zang, Y. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929727 · Cited by 50
Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Ma, J., Yao, Y., Tian, Y., Chen, K., & Liu, B. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00469-5 · Cited by 48
Genetic differences between smokers and never-smokers with lung cancer
Kuśnierczyk, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063716 · Cited by 47
Sex hormones, the anticancer immune response, and therapeutic opportunities
Conforti, F., Pala, L., Mitri, D. D., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., Locatelli, M., Facella, F., Pas, T. M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.013 · Cited by 48
Self-citationYan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45
Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J. D., Enderling, H., Schoenfeld, J. D., Brody, J., McGee, H. M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00656-9 · Cited by 49
Athauda, A., Nankivell, M. G., Langley, R. E., Alderson, D., Allum, W., Grabsch, H. I., Starling, N., Chau, I., & Cunningham, D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.005 · Cited by 43
Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
Vavalà, T., Catino, A., Pizzutilo, P., Longo, V., & Galetta, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111942 · Cited by 44
Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival
Li, W., Lv, S., Liu, G., Hu, L., Xia, W., & Xiang, Y. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00361-8 · Cited by 39
Akbari, H., Taghizadeh‐Hesary, F., & Bahadori, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.12.001 · Cited by 38
Chen, C., Zhang, C., Jin, Z., Wu, B., & Xu, T. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01395-7 · Cited by 37
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities
Zhang, C., Guo, X., Liu, P., Wang, Y., Zhang, J., Li, L., Wu, K., Xiao, J., Mei, Q., & Wang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01748-5 · Cited by 43
m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer
Zhang, C., Liu, J., Guo, H., Hong, D., Ji, J., Zhang, Q., Guan, Q., & Ren, Q. (2021) · Bioengineered · doi:10.1080/21655979.2021.1946305 · Cited by 36
Rousseau, A., Michiels, S., Simon‐Tillaux, N., Lolivier, A., Bonastre, J., Planchard, D., Barlési, F., Remón, J., Lavaud, P., Aldea, M. D., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100970 · Cited by 34
Ninmer, E. K., Zhu, H., Chianese‐Bullock, K. A., von Mehren, M., Haas, N. B., Ross, M. I., Dengel, L. T., & Slingluff, C. L. (2024) · Nature Communications · doi:10.1038/s41467-024-46877-6 · Cited by 35
Sex-biased adaptive immune regulation in cancer development and therapy
Schafer, J. M., Xiao, T., Kwon, H., Collier, K. A., Chang, Y., Abdel-Hafiz, H. A., Bolyard, C. M., Chung, D., Yang, Y., Sundi, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104717 · Cited by 32
Connecting the mechanisms of tumor sex differences with cancer therapy
Li, H., Jiang, W., Liu, S., Yang, M., Chen, S., Pan, Y., & Cui, M. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04723-1 · Cited by 31
The role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 31
Gene regulatory networks reveal sex difference in lung adenocarcinoma
Saha, E., Guebila, M. B., Fanfani, V., Fischer, J., Shutta, K. H., Mandros, P., DeMeo, D. L., Quackenbush, J. F., & Lopes‐Ramos, C. M. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00634-y · Cited by 33
Managing side effects of immune checkpoint inhibitors in breast cancer
Criscitiello, C., Corti, C., Pravettoni, G., & Curigliano, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103354 · Cited by 33
Riaz, I. B., Islam, M., Khan, A. M., Naqvi, S. A. A., Siddiqi, R. L., Khakwani, K. Z. R., Asghar, N., Ikram, W., Hussain, S. A., Singh, P. P., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.03.042 · Cited by 28
Isaksson, J., Berglund, A., Louie, K. S., Willén, L., Hamidian, A., Edsjö, A., Enlund, F., Planck, M., Vikström, A., Johansson, M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.05.002 · Cited by 27
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities
Dotto, G. P., Buckinx, A., Özdemir, B. C., & Simon, C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00772-w · Cited by 26
Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors
Gonzalez, B. D., Eisel, S. L., Bowles, K. E., Hoogland, A. I., James, B. W., Small, B. J., Sharpe, S., Hyland, K. A., Bulls, H. W., Christy, S. M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab171 · Cited by 23
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Parisi, C., Abdayem, P., Tagliamento, M., Besse, B., Planchard, D., Remón, J., Minuti, G., Cappuzzo, F., & Barlési, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102845 · Cited by 28
Gu, H.-Y., Lin, L., Zhang, C., Yang, M., Zhong, H.-C., & Wei, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01317 · Cited by 24
Pérez-Díez, I., Hidalgo, M. R., Malmierca-Merlo, P., Andreu, Z., Romera-Giner, S., Farrás, R., de la Iglesia-Vayá, M., Provencio, M., Romero, A., & Garcia‐García, F. (2021) · Cancers · doi:10.3390/cancers13010143 · Cited by 25
Holtzman, L., Moskovitz, M. T., Urban, D., Nechushtan, H., Keren, S., Reinhorn, D. J., Wollner, M., Daher, S., Rottenberg, Y., Rovitzky, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.12.006 · Cited by 25
Fukuokaya, W., Kimura, T., Komura, K., Uchimoto, T., Nishimura, K., Yanagisawa, T., Imai, Y., Iwatani, K., Ito, K., Urabe, F., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.02.020 · Cited by 24
Nazha, B., Goyal, S., Chen, Z., Engelhart, A., Carlisle, J. W., Beardslee, T. J., Gill, H. S., Odikadze, L., Liu, Y., Mishra, M. K., et al. (2020) · Cancer · doi:10.1002/cncr.33141 · Cited by 23
Ge, Y., Wei, F., Du, G., Fei, G., Li, W., Li, X., Chu, J., & Wei, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-07978-3 · Cited by 23
Boosting anticancer immunotherapy through androgen receptor blockade
Pala, L., Pas, T. M. D., & Conforti, F. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.007 · Cited by 23
Self-citationSex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
Liang, J., Hong, J., Tang, X., Qiu, X., Zhu, K., Zhou, L., & Guo, D. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2124449 · Cited by 25
Tostivint, E. P., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03359-2 · Cited by 26
Development of an updated, standardized, patient-centered outcome set for lung cancer
de Rooij, B. H., van den Hurk, C. J. G., Smaardijk, V. R., Fernández‐Ortega, P., Navarro-Martín, A., Barberio, L., Gückenberger, M., Schmid, S., Walraven, I., Vallow, S., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.021 · Cited by 22
Tsai, L. L., Chu, N.-Q. T., Blessing, W. A., Moonsamy, P., & Colson, Y. L. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.09.060 · Cited by 23
Huang, Y., Cho, H. J., Stranger, B. E., & Huang, R. S. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-1013 · Cited by 23
Pala, L., Pas, T. M. D., & Conforti, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.09.004 · Cited by 23
Self-citationHuang, Y., Zhao, J. J., Soon, Y. Y., Kee, A. C.-L., Tay, S. H., Aminkeng, F., Ang, Y. L. E., Wong, A. S. C., Bharwani, L. D., Goh, B. C., et al. (2023) · Cancers · doi:10.3390/cancers15102733 · Cited by 20
La-Beck, N. M., Nguyen, D. T., Le, A. D., Alzghari, S. K., & Trinh, S. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2364 · Cited by 21
Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
Ferrucci, P. F., Lens, M. B., & Cocorocchio, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01134-7 · Cited by 19
Self-citationNovel immune targets for the treatment of triple-negative breast cancer
Corti, C., Nicolò, E., & Curigliano, G. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006187 · Cited by 21
The effect of patient sex on the efficacy and safety of anticancer immunotherapy
Pala, L., & Conforti, F. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1939672 · Cited by 20
Self-citationSex differences in cancer and immunotherapy outcomes: the role of androgen receptor
Zhao, J., Wang, Q., Tan, A. F., Loh, C. J. L., & Toh, H. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1416941 · Cited by 19
A Machine Learning-Based Investigation of Gender-Specific Prognosis of Lung Cancers
Wang, Y., Liu, S., Wang, Z., Fan, Y., Huang, J., Huang, L., Li, Z., Li, X., Jin, M., Yu, Q., et al. (2021) · Medicina · doi:10.3390/medicina57020099 · Cited by 19
Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M. B., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skúladóttir, H., Kristiansen, C., et al. (2022) · Acta Oncologica · doi:10.1080/0284186x.2021.2023213 · Cited by 19
Toren, P., Brisson, H., Simonyan, D., Hovington, H., Lacombe, L., Bergeron, A., & Fradet, Y. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03358-x · Cited by 18
The Influence of Sex Hormones and X Chromosome in Immune Responses
Anesi, N., Miquel, C., Laffont, S., & Guéry, J. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_2 · Cited by 20
Tsiouda, T., Sardeli, C., Porpodis, Κ., Pilikidou, M., Apostolidis, G., Kyrka, K., Miziou, A., Kyrka, K., Tsingerlioti, Z., Papadopoulou, S. Κ., et al. (2020) · Journal of Cancer · doi:10.7150/jca.40196 · Cited by 20
Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer
Deng, S., Ramos-Castaneda, M. A., Velasco, W. V., Clowers, M. J., Gutierrez, B. A., Noble, O., Dong, Y., Zarghooni, M., Alvarado, L., Caetano, M. S., et al. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa064 · Cited by 18
Bourbonne, V., Geier, M., Schick, U., & Lucia, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061237 · Cited by 17
Li, F., Zhai, S., Lv, Z., Yuan, L., Wang, S., Jin, D., Yi, H., Fu, L., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968517 · Cited by 17
Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific
Li, X., Wei, S., Deng, L., Tao, H., Liu, M., Zhao, Z., Du, X., Li, Y., & Hou, J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02387-7 · Cited by 18
Sex-related differences in the efficacy and toxicity of cancer treatments
Santaballa, A., Rodríguez, J. A. M., Cardeña-Gutiérrez, A., Callejo, V. M., Higuera, O., Bernárdez, B., Moreno, E., & Majem, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03893-2 · Cited by 17
Hunt, K. S., & Alspach, E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0005 · Cited by 17
Wiesweg, M., Küter, C., Schnorbach, J., Keyl, J., Metzenmacher, M., Cvetkovic, J., Saalfeld, F. C., Glanemann, F., Eberhardt, W., Öezkan, F., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35199 · Cited by 17
Metadata
- Authors
- Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., De Marinis, F., Gelber, R. D., & Goldhirsch, A.
- Affiliations
- See the Notes section for the full list of authors’ affiliations
- Corresponding author
- Conforti, Fabio
- ORCID
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-20
- Volume
- 111
- Issue
- 8
- Pages
- 772-781
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC6695312
- OpenAlex
- W2946644285
- Cited by
- 262
- References
- 34
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 56 · 2023: 36 · 2022: 36 · 2021: 39 · 2020: 28 · 2019: 4
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sex differences, lung cancer immunotherapy, immune checkpoint inhibitors, anti-PD-1, PD-L1 inhibitors, anti-CTLA-4, non-small cell lung cancer, combination chemotherapy, overall survival, first-line systemic treatment
- MeSH terms
- Female, Humans, Immunotherapy, Lung Neoplasms, Male, Sex Characteristics, Disease-Free Survival, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
